IMG-007 has the potential to provide Q12W or less frequent dosing based on an extended half-life IMG-007 has demonstrated a favorable safety profile, consistent with a silenced ADCC function via bioengineering IMG-007 is being evaluated in two global proof-of-concept trials SAN DIEGO, Aug….